5th Oligonucleotides Analytical Development and CMC
August 17 - 19, 2026 - MA USHanson Wade Conferences Ltd
info@hansonwade.com
Phone:6174554188
As oligonucleotide therapeutics expand across ASOs, siRNA, gRNA, and increasingly complex conjugates, the field is entering a new phase of clinical and commercial maturity. However, with this progress comes heightened complexity across analytical characterization, impurity profiling, stereochemistry, and control strategy definition, increasing pressure for development teams to deliver robust, scalable, and regulatory-ready CMC packages. With evolving European and Chinese guidance and increasing global expectations for analytical depth, comparability, and justification of control strategies, success now hinges on the ability to the ability to predict, monitor, and control impurity formation throughout development and manufacturing. To meet these demands, the 5th Oligonucleotide Analytical Development and CMC Summit returns to unite 90+ leaders across Analytical Development, CMC, Quality Control, Process Development, and Regulatory Affairs to define best practices and establish the next standard for oligonucleotide control strategies. Time: 08:30 to 15:05